{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:34:21Z","timestamp":1791135261610,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ygyno.2014.06.029","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T06:16:42Z","timestamp":1404973002000},"page":"478-485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma"],"prefix":"10.1016","volume":"134","clinical-trial-number":[{"clinical-trial-number":"nct00721162","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Richard T.","family":"Penson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Braly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Schimp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Haluska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane C.","family":"Bodurka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca R.","family":"Hozak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.06.029_bb0005","first-page":"63","article-title":"Cancer statistics, 2012","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/joim.12019","article-title":"VEGFA and tumour angiogenesis","volume":"273","author":"Claesson-Welsh","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3816\/CLC.2010.n.039","article-title":"Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"11","author":"Subramanian","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1016637700638","article-title":"Involvement of VEGFR-2 (kdr\/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro","volume":"4","author":"Koolwijk","year":"2001","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0025","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1242\/dev.126.7.1407","article-title":"VEGF deprivation-induced apoptosis is a component of programmed capillary regression","volume":"126","author":"Meeson","year":"1999","journal-title":"Development"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1006094117427","article-title":"Monoclonal antibodies targeting the VEGF receptor-2 (Flk1\/KDR) as an anti-angiogenic therapeutic strategy","volume":"17","author":"Witte","year":"1998","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1568009023333881","article-title":"Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics","volume":"2","author":"Zhu","year":"2002","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0040","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0045","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0050","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0055","series-title":"Molecular targets and cancer therapeutics","first-page":"B2007","article-title":"Phase I dose-escalation study of the anti-VEGFR-1 recombinant human IgG1 MAb IMC-1121B administered every other weeks (q2W) or every 3 (q3w) in patients (pts) with advanced cancers","author":"Chiorean","year":"2007"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0060","doi-asserted-by":"crossref","first-page":"43496","DOI":"10.1074\/jbc.M307742200","article-title":"Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity","volume":"278","author":"Lu","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0065","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2402831","article-title":"Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity","volume":"17","author":"Zhu","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0080","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0085","first-page":"CD007930","article-title":"Angiogenesis inhibitors for the treatment of ovarian cancer","author":"Gaitskell","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0095","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1158\/1078-0432.CCR-04-0683","article-title":"Recurrent ovarian cancer: how important is it to treat to disease progression?","volume":"10","author":"Herzog","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0105","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1002\/cncr.26540","article-title":"Mechanisms of resistance to vascular endothelial growth factor blockade","volume":"118","author":"Abdullah","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0110","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0115","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1158\/1078-0432.CCR-11-1275","article-title":"Combining antiangiogenics to overcome resistance: rationale and clinical experience","volume":"18","author":"Moreno Garcia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.06.029_bb0120","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.hoc.2012.01.009","article-title":"Targeting angiogenesis in gynecologic cancers","volume":"26","author":"Zand","year":"2012","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814010701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814010701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:35:47Z","timestamp":1758771347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814010701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0090825814010701"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.029","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}